The growing use of GLP-1 drugs has raised many questions within the scientific community regarding the approach adopted to tackle obesity and diabetes. The management of these conditions appears to go beyond simple lifestyle changes, moving toward more structured and “pharmacological” strategies.

This shift is particularly evident in the Middle East, where rising obesity rates have reached a level that is difficult to sustain from both a healthcare and social perspective. In many Gulf countries, obesity has moved from being a marginal condition to becoming a complex chronic disease, closely linked to other equally concerning conditions: type 2 diabetes, cardiovascular risk, and metabolic syndrome. Data shows steady growth, with a direct impact on both people’s quality of life and the resilience of healthcare systems, which are increasingly exposed to high costs and the management of related conditions.

In this context, GLP-1 receptor agonists have emerged as one of the most effective responses, delivering significant clinical results in weight loss and improvement of metabolic parameters. Their ability to act on appetite, blood glucose, metabolism and body weight has helped redefine expectations among both physicians and patients, opening a new phase in obesity treatment.

However, this therapeutic revolution brings with it a level of complexity that is often underestimated. Alongside the benefits, side effects, challenges in treatment adherence and the risk of weight regain after discontinuation highlight how pharmacological treatment alone is not sufficient to guarantee long-term results.

A new clinical need is therefore emerging: to support pharmacological therapy with a broader approach capable of sustaining metabolism over time and managing the critical aspects associated with these treatments.

The obesity emergency in the Middle East: a healthcare and economic crisis

In the Middle East, obesity has reached a structural dimension. In many Gulf countries, it affects a large share of the population and is directly linked to the rise of type 2 diabetes, cardiovascular diseases, and metabolic disorders. The data describes a scenario that requires continuous and coordinated intervention with 21,2% obesity and 33,1% overweight (Journal of Obesity, 2022)1 , as it impacts individual health, but also the ability of healthcare systems to effectively manage chronic diseases.

Obesity as a chronic disease in Gulf countries

Today, obesity is (rightly) treated as a complex chronic disease. It is in fact a multifactorial condition, meaning that it depends on a combination of biological, environmental, and behavioral factors. In Gulf countries, several dynamics have contributed to the spread of overweight.

Consider, for example, rapid urbanization, changes in dietary habits, and reduced physical activity. All of these elements have accelerated the process and make it more difficult to intervene with traditional tools. This complexity also explains why many strategies based solely on diet and physical activity struggle to produce stable long-term results.

Epidemiological data and differences between countries

Differences across countries highlight how deeply rooted the phenomenon is. In Kuwait, for example, female obesity rates exceed 48% (and in some cases reach up to 55% of the population), while male rates are lower. Similar situations are observed in Saudi Arabia and the United Arab Emirates, where obesity prevalence continues to rise alongside increasing cardiometabolic risk.

The data analyzed also show that obesity plays a key role in the development of several cardiovascular diseases, including coronary heart disease, heart failure, and atrial fibrillation. At a global level, the proportion of cardiovascular diseases directly attributable to obesity varies significantly between 0.3% and 19.8% depending on the country.

Among these conditions, heart failure appears to be the most influenced by excess weight, accounting for approximately 11.5% of total cases. This is followed by atrial fibrillation at around 9%, and coronary heart disease at about 4%.

Geographical analysis shows that the burden of obesity-related cardiovascular diseases is particularly critical in countries such as Syria, Kuwait and Iraq, where high obesity prevalence amplifies the epidemiological impact of these conditions. Gender dynamics also show relevant disparities, with risk fractions ranging between 3.6% and 10.5% in men, while in women the impact is significantly higher, ranging from 4.7% up to 13.4%.2

This imbalance across population groups highlights the need for targeted strategies, as the issue does not follow a single dynamic and requires context-specific interventions.

The economic burden of obesity in Gulf countries

The impact of obesity goes beyond the clinical dimension. In Gulf countries, the rise in weight-related conditions directly affects healthcare spending and the sustainability of public systems. Data from the World Obesity Federation indicate that by 2035, obesity could account for over 4% of GDP in the United Arab Emirates, with a total cost (direct and indirect) of23.21 billion dollars.3

Impact on healthcare systems and GDP

The increase in cases of diabetes, cardiovascular diseases and metabolic syndrome places constant pressure on healthcare systems. Costs involve not only direct treatments, but also long-term monitoring, hospitalizations, and complication management. This scenario requires increasing resources and challenges the ability of systems to ensure continuity of care on a large scale.

Productivity, labor, and economic sustainability

Obesity also affects the productive sector. Associated conditions lead to increased absenteeism and reduced operational efficiency. In the long term, this translates into a loss of productivity that impacts the overall economy.

GLP-1 drugs and weight management: the transformation of obesity treatment

In recent years, obesity pharmacotherapy has introduced more effective tools compared to the past. GLP-1 receptor agonists, in particular, act on biological mechanisms that influence body weight, as they are linked to appetite regulation and metabolism.

GLP-1 receptor agonists: what they are and why they are changing everything

So, what is GLP-1? It is a hormone produced by the intestine that regulates several metabolic processes. Drugs that mimic its action increase satiety, slow gastric emptying and help control blood glucose levels.

This combined action makes it possible to intervene more precisely on eating behaviour and metabolism, reducing caloric intake without resorting to drastic restrictions. The result is a more controlled weight loss and, in many cases, more sustainable over time.

Semaglutide and Tirzepatide: how GLP-1 drugs work

Among the most commonly used molecules are semaglutide (Wegovy®, Ozempic®) and tirzepatide (Mounjaro®). The former acts as a GLP-1 agonist and has demonstrated in clinical trials a weight reduction of over 15%.4 The latter introduces a broader mechanism, as it also acts on the GIP receptor, producing a stronger effect on metabolism and appetite.

These drugs also act on visceral fat, which represents one of the main risk factors for cardiometabolic diseases. Their use, therefore, has an impact that goes beyond the number on the scale and involves broader clinical parameters related to overall metabolic health.

Risks and benefits: the clinical impact of GLP-1 drugs

The effectiveness of GLP-1 drugs has led many healthcare systems to consider them a concrete tool in obesity management. Clinical results show significant improvements across several parameters, but real-world patient experience also highlights critical issues that affect treatment continuity. Understanding both aspects allows for a more complete evaluation of the role of these therapies.

Benefits beyond weight loss

The impact of these therapies is systemic. First of all, the effects of GLP-1 drugs on blood sugar are particularly relevant, as they have proven highly effective in glycemic control. They also reduce blood pressure and help rebalance the lipid profile. Some studies have shown a reduction in cardiovascular risk even in patients without diabetes, confirming an effect that goes beyond weight loss.

Their action on metabolism also involves the liver and visceral fat, with clinical benefits observed in patients with hepatic steatosis. This set of effects makes GLP-1 drugs important tools in managing cardiometabolic risk, especially in contexts where these conditions are widespread.

Side effects of GLP-1 drugs: the real challenge of the therapy

It is important to remember that the use of GLP-1 drugs involves side effects that influence the patient’s experience from the early stages of treatment. The most common issues affect the gastrointestinal tract and include nausea, vomiting, constipation and reflux. These symptoms tend to appear during dose escalation and may affect adherence to therapy.

Alongside the more common effects, there are less frequent but clinically relevant conditions such as pancreatitis and gallstones. Another aspect concerns the loss of muscle mass, which can accompany weight loss if not managed with adequate nutritional support and targeted physical activity.

Muscle loss is mainly caused by a strong caloric and protein deficit, combined with the activation of catabolic processes and a reduction in anabolic hormones (such as IGF-1). This phenomenon is exacerbated by a sedentary lifestyle and side effects such as nausea and early satiety, which further limit nutrient intake.

To preserve muscle mass and ensure healthy weight loss, the following are necessary:

  • consistent resistance training (2–3 times per week);
  • a high-protein diet (at least 1.6 g/kg of body weight);
  • regular monitoring of body composition through BIA or DEXA;
  • gradual dose management to minimize dietary side effects.

There may also be effects of diabetes drugs on sex life, as treatment influences multiple dimensions of health.

Overall, these are significant side effects that require constant monitoring and careful management of the therapeutic pathway.

Treatment adherence and early discontinuation

A significant proportion of patients discontinue treatment earlier than expected, often due to side effects, high drug costs or difficulty maintaining the therapeutic pathway over time. A recent population-based analysis in Denmark revealed that over 50% of patients initiated on GLP-1 receptor agonists, specifically semaglutide, ceased treatment within the first year.5

This interruption raises a central issue in obesity management: what happens after the drug is discontinued. The answer to this question becomes crucial in evaluating the real long-term effectiveness of the therapy.

The rebound problem: what happens when GLP-1 therapy is stopped

Stopping GLP-1 drugs opens a delicate phase of the therapeutic pathway. During treatment, the drug modulates the signals that regulate hunger and satiety. When this support is removed, the balance built over time can change rapidly, and the patient must manage stronger physiological stimuli again.

Research from JAMA Internal Medicine (Nov 2025) shows that after 36 weeks on tirzepatide, patients who switched to a placebo struggled with weight maintenance. Within a year of stopping the drug, 82% of those who lost weight regained a quarter or more of it. Furthermore, as weight returned, the metabolic benefits—such as improved cholesterol and blood sugar levels—began to disappear.6

Why weight tends to return

One of the most evident effects is the return of so-called “food noise,” meaning the constant thoughts related to food. Without the drug’s action, the sense of satiety decreases and appetite regulation returns to pre-treatment levels. This can lead to an increase in caloric intake and, over time, weight regain.

Another factor must be considered: during weight loss, part of lean mass may decrease. The loss of muscle mass and lean mass slows metabolism and makes it more difficult to maintain achieved results, especially without targeted nutritional and physical activity strategies.

EuPower protects lean mass during GLP-1 RAs therapy
EuPower protects lean mass during GLP-1 RAs therapy

To protect lean muscle mass, Cor.Con. International has developed a dietary supplement designed for individuals undergoing GLP-1 receptor agonist therapy. EuPower, formulated with creatine monohydrate, HMB (beta-hydroxy-beta-methylbutyrate), and vitamin D, should be combined with appropriate physical activity and adequate protein intake.

Limits of a pharmacological-only approach

Pharmacological intervention acts on specific physiological mechanisms, but it does not automatically change habits, behaviours, and the context in which the metabolic condition develops.

When the therapeutic pathway relies only on the drug, maintaining results becomes more complex. This is why weight management requires an integrated approach that takes all these factors into account.

Beyond the drug: the need for an integrated metabolic approach

Managing obesity requires continuity over time. GLP-1 drugs act on specific mechanisms and deliver significant results, but the process does not end with pharmacological therapy. Side effects, metabolic adaptation, and the post-treatment phase require tools that support the patient beyond the therapy itself.

Why GLP-1 drugs alone are not enough

During treatment, many patients experience gastrointestinal issues, appetite changes, and shifts in body composition. These aspects affect quality of life and may lead to block treatment earlier than expected. In addition, the post-treatment phase exposes patients to the risk of regaining weight, especially if metabolism has not been adequately supported.

The role of nutritional and metabolic support

The work of Cor.Con. International focuses precisely on supporting pharmacological therapies through nutritional integration. The goal is to develop solutions for metabolic well-being through scientific research, clinical studies, and targeted formulations. Their supplements for the metabolic system support patients with specific substances to counteract the cellular effects of oxidative stress, but also to limit the absorption of lipids and fatty acids.

Lipiban Metabolic System supplement
Lipiban Metabolic System supplement

Integrating pharmacological therapy with metabolic support allows for a more stable pathway, where the patient does not rely on a single lever but can count on a broader and continuous strategy.

The challenge of access to GLP-1 drugs in the Middle East

The spread of GLP-1 drugs in Gulf countries faces concrete limitations related to cost, availability, and healthcare system organization. Access to these therapies, in fact, remains uneven and often depends on the patient’s financial capacity or local health policies.

The high cost of these treatments represents one of the main barriers. Availability is also not always consistent: growing demand has created shortages that complicate treatment continuity.

Limited access has also encouraged the spread of unsafe alternative solutions, often lacking any prior clinical oversight. Some patients therefore turn to unregulated channels or non-certified preparations.

The future of obesity in the Middle East: innovation and accessibility

Advances in research are expanding treatment possibilities. In particular, new methods of administration are being explored, including oral formulations that eliminate the need for weekly injections.

In the coming years, the main objective will be to reduce costs in order to facilitate access to therapies. Wider availability of treatments could enable earlier intervention on cardiometabolic risk, with concrete benefits for public health and healthcare system sustainability.

Ultimately, the future of obesity management will depend on the ability to integrate pharmacological innovation, metabolic support, and long-term therapeutic continuity.

References

  1. Okati-Aliabad, Hassan, Ansari-Moghaddam, Alireza, Kargar, Shiva, Jabbari, Neda, “Prevalence of Obesity and Overweight among Adults in the Middle East Countries from 2000 to 2020: A Systematic Review and Meta-Analysis”, Journal of Obesity, 2022, 8074837, 18 pages, 2022. https://doi.org/10.1155/2022/8074837 ↩︎
  2. Okati-Aliabad, Hassan, Ansari-Moghaddam, Alireza, Kargar, Shiva, Jabbari, Neda, “Prevalence of Obesity and Overweight among Adults in the Middle East Countries from 2000 to 2020: A Systematic Review and Meta-Analysis”, Journal of Obesity, 2022, 8074837, 18 pages, 2022. https://doi.org/10.1155/2022/8074837 ↩︎
  3. Global Obesity Observatory ↩︎
  4. Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes Metab. 2023 Jan;25(1):18-35. doi: 10.1111/dom.14863. Epub 2022 Oct 18. PMID: 36254579; PMCID: PMC10092086. ↩︎
  5. Mailhac A, Pedersen L, Petersen I, Pottegård A, Sørensen HT, Thomsen RW. Discontinuation of semaglutide therapy for weight loss: population-based study of the first 77,310 users in Denmark. Presented at: European Association for the Study of Diabetes (EASD) Annual Meeting; September 15-19, 2025; Vienna, Austria. ↩︎
  6. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026;186(2):157–167. doi:10.1001/jamainternmed.2025.6112 ↩︎